A retrospective case series of ultrasound-guided suprascapular nerve pulsed radiofrequency treatment for hemiplegic shoulder pain in patients with chronic stroke

• Published in: Journal of pain research 2018-01, Vol.11, p.1115-1120
• Main Authors: Picelli, Alessandro, Lobba, Davide, Vendramin, Patrizia, Castellano, Giuseppe, Chemello, Elena, Schweiger, Vittorio, Martini, Alvise, Parolini, Massimo, Gandolfi, Marialuisa, Polati, Enrico, Smania, Nicola
• Format: Article
• Language: English
• Subjects: Botulinum toxin; Bupivacaine; Care and treatment; Chronic pain; Heat; Intensive care; Neurosciences; Original Research; Pain; Pain management; Patients; Rehabilitation; Rotator cuff; Shoulder; Shoulder pain; Stroke; Stroke patients; Ultrasonic imaging
• ISSN: 1178-7090; 1178-7090
• DOI: 10.2147/JPR.S160622

Hemiplegic shoulder pain (HSP) is the most common pain condition after stroke. Pulsed radiofrequency (PRF) treatment of the suprascapular nerve (SSN) effectively relieves shoulder pain conditions. To date, there is no study about the effects of PRF treatment for HSP. Thus, our aim was to report on a case series about its use in chronic stroke. Six chronic stroke patients with HSP (visual analog scale [VAS] score for pain ≥30 mm) underwent ultrasound-guided SSN PRF treatment. All were evaluated before treatment and at 4 and 16 weeks of follow-up. The main outcome was VAS score. Secondary outcomes were Modified Ashworth Scale, shoulder passive range of motion (PROM), Disability Assessment Scale (DAS), Fugl-Meyer Assessment, and EuroQol-5 dimension questionnaire (EuroQol-5D) scores. As compared with baseline, improvement was observed in the following parameters: VAS for pain (at 4 weeks, =0.023; at 16 weeks, =0.023); shoulder PROM for abduction (at 4 weeks, =0.023; at 16 weeks, =0.024), flexion (at 4 and 16 weeks, =0.024), extension (at 4 and 16 weeks, =0.02), and external rotation (4 and 16 weeks, =0.02); DAS for hygiene (at 4 and 16 weeks, =0.024), dressing (at 4 weeks, =0.02; at 16 weeks, =0.024), and pain (at 4 weeks, =0.024; at 16 weeks, =0.023); and EuroQol-5D (at 4 and 16 weeks, =0.024). Our observations support the use of ultrasound-guided SSN PRF treatment for HSP in chronic stroke patients.